Neoadjuvant combination checkpoint blockade trial yields high response rates for patients with high-risk stage three melanoma

Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage three melanoma, with nearly half having no sign of disease at surgery, but a high incidence of side effects caused the trial to be closed early.

from Latest Science News -- ScienceDaily https://ift.tt/2yfXvBR

Comments

Popular posts from this blog

Jared Leto Was Responsible for the "We Live in a Society" Line in the 'Zack Snyder's Justice League' Trailer - /FILM

How to keep Amazon, Apple, and Google from listening to your Alexa, Siri, and Assistant recordings - TechHive

Exclusive: IAEA found uranium traces at Iran 'atomic warehouse' - diplomats - Reuters